Mutation analysis of ovarian carcinoma patients presenting optimal response to neoadjuvant chemotherapy

被引：0
|
作者：
Rouleau, Etienne [1 ]
dos Santos, Elizabeth Santana [2 ]
Maela, Francilette [1 ]
Lacroix, Ludovic [1 ]
Auguste, Aurelie [1 ]
Pautier, Patricia [1 ]
Morice, Philippe [1 ]
Genestie, Catherine [1 ]
Leary, Alexandra [1 ]
机构：
[1] Inst Gustave Rousy, Villejuif, France
[2] AC Camargo Canc Ctr, Sao Paulo, Brazil
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-3504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3504
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mutation analysis of ovarian carcinoma patients presenting optimal response to neoadjuvant chemotherapy
    Dos Santos, E. S.
    Galende, E. Yaniz
    Caputo, S. M.
    da Costa, A. A. B. A.
    Nashvi, M.
    Maella, F.
    Lacroix, L.
    Auguste, A.
    Le Formal, A.
    De Brot Andrade, L.
    Miranda, V. C.
    Diz, M. D. P. E.
    Vasconcelos, M.
    Pautier, P.
    Morice, P.
    Genestie, C.
    Leary, A.
    Rouleau, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S814 - S814
  • [2] Neoadjuvant Chemotherapy for Elderly Patients with Advanced Stage Ovarian Carcinoma
    Salman, Lina
    Ben-Haroush, Avi
    Sabah, Gad
    Jakobson-Setton, Ariella
    Tsoref, Daliah
    Raban, Oded
    Yeoshoua, Effi
    Eitan, Ram
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2020, 22 (02): : 75 - 78
  • [3] NEOADJUVANT CHEMOTHERAPY FOR ELDERLY PATIENTS WITH ADVANCED STAGE OVARIAN CARCINOMA
    Salman, L.
    Ben-Haroush, A.
    Sabah, G.
    Jakobson-Setton, A.
    Tsoref, D.
    Raban, O.
    Yeoshoua, E.
    Eitan, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 822 - 824
  • [4] THE PROGNOSTIC VALUE OF HEMATOLOGIC INDICES IN OVARIAN CARCINOMA PATIENTS TREATED BY NEOADJUVANT CHEMOTHERAPY, IS IT MEDIATED BY CHEMOTHERAPY RESPONSE SCORE?
    Joubran, Jumana
    Aizek, Asaf
    Laskov, Ido
    Grisaru, Dan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A309 - A310
  • [5] Predicting response to neoadjuvant chemotherapy (NAC) in epithelial ovarian carcinoma (EOC).
    Montes, A.
    Okera, M.
    Ayis, S.
    Natas, S.
    Jacques, A.
    Winship, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Predictors for optimal cytoreduction following neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
    de Jong, D.
    Dodge, J. E.
    Freedman, O.
    Lo, E.
    Rosen, B. P.
    Mackay, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] RADIOLOGICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY AS INDICATOR OF OPTIMAL CYTOREDUCTION IN ADVANCED OVARIAN CANCER
    Maricic, S.
    Mandic, A.
    Bunovic, N. Prvulovic
    Stojanovic, S.
    Stojic, I.
    Stanulovic, N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A117 - A117
  • [8] Neoadjuvant chemotherapy in advanced ovarian cancer: optimal patient selection and response evaluation
    Cho, Jae Hyun
    Kim, Seik
    Song, Yong Sang
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (06)
  • [9] Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients
    Vergote, I
    De Wever, I
    Tjalma, W
    Van Gramberen, M
    Decloedt, J
    van Dam, P
    GYNECOLOGIC ONCOLOGY, 1998, 71 (03) : 431 - 436
  • [10] The role of neoadjuvant chemotherapy in advanced ovarian carcinoma
    Vergote, IB
    De Wever, I
    Tjalma, W
    Van Gramberen, M
    Van Dam, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S305 - S305
12345